402 related articles for article (PubMed ID: 21284497)
1. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Myers GM; Mayer KH
AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
[TBL] [Abstract][Full Text] [Related]
2. Considerations regarding antiretroviral chemoprophylaxis in MSM.
Poynten IM; Zablotska I; Grulich AE
Curr Opin HIV AIDS; 2012 Nov; 7(6):549-56. PubMed ID: 22918448
[TBL] [Abstract][Full Text] [Related]
3. [HIV preexposure prophylaxis].
Olczak A; Grabczewska E
Przegl Epidemiol; 2012; 66(1):79-82. PubMed ID: 22708303
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Okwundu CI; Uthman OA; Okoromah CA
Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
[TBL] [Abstract][Full Text] [Related]
5. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
Celum C; Baeten JM
Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
[TBL] [Abstract][Full Text] [Related]
7. Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
Clercq ED
Biochem Pharmacol; 2012 Mar; 83(5):567-73. PubMed ID: 22067069
[TBL] [Abstract][Full Text] [Related]
8. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
[TBL] [Abstract][Full Text] [Related]
9. HIV preexposure prophylaxis: new data and potential use.
Celum CL
Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
[TBL] [Abstract][Full Text] [Related]
11. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
Baeten JM; Haberer JE; Liu AY; Sista N
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
[TBL] [Abstract][Full Text] [Related]
12. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Plosker GL
Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
[TBL] [Abstract][Full Text] [Related]
13. Oral antiretroviral chemoprophylaxis: current status.
Baeten J; Celum C
Curr Opin HIV AIDS; 2012 Nov; 7(6):514-9. PubMed ID: 22964886
[TBL] [Abstract][Full Text] [Related]
14. Preexposure prophylaxis for the prevention of HIV transmission to women.
Aaron E; Cohan D
AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
[TBL] [Abstract][Full Text] [Related]
15. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
[TBL] [Abstract][Full Text] [Related]
16. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB
Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402
[TBL] [Abstract][Full Text] [Related]
17. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Aug; 61(31):586-9. PubMed ID: 22874836
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A
HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390
[TBL] [Abstract][Full Text] [Related]
19. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(3):65-8. PubMed ID: 21270743
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
